Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Chlorowodorek pazopanibu w leczeniu pacjentów z zaawansowanymi lub opornymi na leczenie guzami litymi

10 listopada 2026 zaktualizowane przez: National Cancer Institute (NCI)

Farmakokinetyczna indywidualizacja terapii pazopanibem u pacjentów z guzami litymi: badanie fazy I

This phase I trial studies the side effects and the best dose of pazopanib hydrochloride in treating patients with solid tumors that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or does not respond to treatment (refractory). Pazopanib hydrochloride may prevent the growth of new blood vessels that tumors need to grow. Studying samples of blood in the laboratory from patients receiving pazopanib hydrochloride may help doctors learn more about the effects of the body on the drug. It may also help doctors understand how well patients respond to treatment.

Przegląd badań

Szczegółowy opis

PRIMARY OBJECTIVES:

I. To assess the feasibility and safety of individualizing pazopanib (pazopanib hydrochloride) monotherapy based upon attained pazopanib plasma concentrations so as to achieve desired target pazopanib plasma concentration in the highest possible fraction of treated patients.

SECONDARY OBJECTIVES:

I. To assess whether patient cytochrome P450 (CYP) or other polymorphisms may correlate with attained pazopanib levels in response to standard pazopanib dosing.

II. To assess whether patient trough pazopanib levels attained 24 hours after initiation of 800 mg daily fasting may predict steady state trough pazopanib levels after 14 days of pazopanib administration.

III. To assess whether patient trough pazopanib levels may correlate with observed pazopanib toxicities.

OUTLINE: This is a dose-escalation study.

Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Course length can be extended to 56 days at the discretion of the treating physician after 12 courses (1 year) of treatment on study.

After completion of study treatment, patients are followed up for 3 months.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

54

Faza

  • Faza 1

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Florida
      • Jacksonville, Florida, Stany Zjednoczone, 32224-9980
        • Mayo Clinic in Florida
    • Minnesota
      • Rochester, Minnesota, Stany Zjednoczone, 55905
        • Mayo Clinic in Rochester

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Histologic proof of cancer which is now not amenable to alternative curative or clearly superior standard treatment options
  • Measurable disease
  • Hemoglobin (Hgb) >= 8.0 g/dL
  • Absolute neutrophil count (ANC) >= 1,500/uL
  • Platelet (PLT) = 100,000/uL
  • Activated partial thromboplastin time (APTT) < 1.2 times upper limit of normal (ULN); (Note: use of warfarin is prohibited; low molecular weight heparin is allowed, so long as these criteria are met)
  • International normalized ratio (INR) < 1.2 times ULN; (Note: use of warfarin is prohibited; low molecular weight heparin is allowed, so long as these criteria are met)
  • Direct bilirubin =< 1.5 X upper limit of normal (ULN) (subjects with Gilbert's syndrome and elevations of indirect bilirubin only are eligible)
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 X ULN
  • Creatinine =< 1.5 times ULN OR measured creatinine clearance of >= 60 mL/min 1.73 m^2
  • Urine protein/creatinine ratio < 1 or 24-hour urine < 1 gram
  • < Grade 2 hypo/hyperkalemia
  • < Grade 3 hypo/hypercalcemia
  • < Grade 3 hypo/hyperphosphatemia
  • < Grade 3 hypo/hypermagnesemia
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
  • Ability to provide informed consent
  • Willing to return to Mayo Clinic for follow up
  • Life expectancy >= 84 days (3 months)
  • Willingness to provide mandatory blood samples for pazopanib drug level assessments required for dosage adjustments, as well as for required pharmacogenomic studies
  • Women of childbearing potential only: negative serum pregnancy test done =< 14 days prior to registration

Exclusion Criteria:

  • Known standard therapy for the patient's disease that is potentially curative or definitely capable of extending life expectancy

  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

  • Corrected QT interval (QTc) >= 480 msec and/or receiving any concomitant medications that are associated with a risk of QTc prolongation and/or torsades de pointes; NOTE: these medications should be discontinued or replaced with drugs that do not carry these risks

  • Subjects with any of the following cardiovascular conditions within the past 6 months

    • Cerebrovascular accident (CVA) or transient ischemic attack (TIA)
    • Admission for unstable angina
    • Myocardial infarction
    • Cardiac angioplasty or stenting
    • Coronary artery bypass graft surgery
    • Pulmonary embolism, untreated deep venous thrombosis (DVT) or DVT which has been treated with therapeutic anticoagulation for less than 6 weeks
    • Arterial thrombosis
    • Symptomatic peripheral vascular disease
    • Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system; a subject who has a history of class II heart failure and is asymptomatic on treatment may be considered eligible
    • Active cardiac arrhythmia (except sinus arrhythmia, atrial fibrillation, asymptomatic premature ventricular contractions [PVCs])
    • Ejection fraction < institutional lower limit of normal (LLN) and/or history of cardiomyopathy
  • Receiving a medication with known risk of torsades de pointes; the following medications are specifically prohibited: amiodarone, arsenic trioxide, bepridil, chloroquine, chlorpromazine, cisapride, clarithromycin, disopyramide, dofetilide, dolasetron, droperidol, erythromycin, halofantrine, haloperidol, ibutilide levomethadyl, mesoridazine, methadone, pentamidine, pimozide, procainamide, quinidine, sotalol, sparfloxacin, and thioridazine; patients should be watched carefully for indications of torsades de pointes, such as syncope; performing additional electrocardiograms (EKGs) on subjects who must take one or more of these medications is not required; however, additional investigations, including EKGs, may be performed as per the treating physician's judgment

  • Blood pressure (BP) > 140 mmHg (systolic) and > 90 mmHg (diastolic); initiation or adjustment of BP medication is permitted prior to registration provided that the average of three BP readings at a visit prior to registration is < 140/90 mmHg

  • Any of the following prior therapies:

    • Chemotherapy =< 28 days prior to registration
    • Mitomycin C/nitrosoureas =< 42 days prior to registration
    • Immunotherapy =< 28 days prior to registration
    • Biologic therapy =< 28 days prior to registration
    • Radiation therapy =< 28 days prior to registration
    • Radiation to > 25% of bone marrow
  • Failure to fully recover from acute, reversible effects of prior chemotherapy (other anti-neoplastic therapy) and radiation therapy

  • Subjects with known brain metastases

  • Any of the following:

    • Pregnant women
    • Nursing women
    • Men or women of childbearing potential who are unwilling to employ adequate contraception
  • Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation); Note: concomitant use of zoledronic acid, pamidronate or denosumab is allowed (and can be initiated while patients are on study therapy at investigator discretion)

  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens

  • Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 counts < 200

  • Receiving any other investigational agent

  • Other active malignancy =< 3 years prior to registration; EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of the cervix; NOTE: if there is a history or prior malignancy, they must not be receiving other specific treatment (e.g. hormonal or chemotherapy) for their cancer

  • Prior use of pazopanib (prior use of other kinase inhibitors allowed)

  • Receiving any medications or substances that are strong or moderate inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) (indinavir, nelfinavir, atazanavir, ritonavir, clarithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, saquinavir, telithromycin, aprepitant, erythromycin, fluconazole, grapefruit juice, verapamil, diltiazem); use of the aforementioned strong or moderate inhibitors is prohibited < 7 days prior to registration

  • Receiving any medications or substances that are inducers of CYP3A4 (efavirenz, nevirapine, carbamazepine, modafinil, phenobarbital, phenytoin, pioglitazone, rifabutin, rifampin, St. John's wort); use of the aforementioned inducers is prohibited =< 7 days prior to registration

  • Receiving mitotane within 6 months of enrolling on the study

  • Subjects with any condition that may impair the ability to swallow or absorb oral medications/investigational product including:

    • Any lesion, whether induced by tumor, radiation or other conditions, which makes it difficult to swallow capsules or pills
    • Prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel
    • Active peptic ulcer disease
    • Malabsorption syndrome
  • Any of the following conditions:

    • Serious or non-healing wound, ulcer, or bone fracture
    • Current use of therapeutic warfarin; Note: low molecular weight heparin is allowed; prothrombin time (PT)/partial thromboplastin time (PTT) must meet the inclusion criteria
    • History of bleeding disorder, including patients afflicted with hemophilia, disseminated intravascular coagulation, or any other abnormality of coagulation potentially predisposing patients to bleeding
    • History of hemoptysis in excess of 2.5 mL (1/2 teaspoon ) within 8 weeks prior to first dose of study drug
    • Poorly controlled depression or anxiety disorder, or recent (=< 6 months) suicidal ideation
    • HIV-positive patients on combination antiretroviral therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
  • Subjects with any condition that may increase the risk of gastrointestinal bleeding or gastrointestinal perforation, including

    • Active peptic ulcer disease
    • Known intraluminal metastatic lesions
    • Inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease) or other gastrointestinal conditions which increase the risk of perforation
    • History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 28 days prior to beginning study treatment

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Treatment (pazopanib hydrochloride)

Patients receive pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Course length can be extended to 56 days at the discretion of the treating physician after 12 courses (1 year) of treatment on study.

Correlative studies

Given PO

Inne nazwy:
  • GW786034B
  • Votrient
  • Pazopater
  • GW-786034B

Correlative studies

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Biologicznie optymalna dawka (BZT) zdefiniowana jako poziom dawki i dieta w kombinacji, która nie wywołuje toksyczności wymagającej modyfikacji dawki zgodnie z protokołem i pozwala osiągnąć zadowalające minimalne stężenie pazopanibu (Cmin większe niż 30 μg/ml)
Ramy czasowe: Po 14 dniach
Po 14 dniach
Czas do pojawienia się jakiejkolwiek toksyczności związanej z leczeniem, zgodnie z oceną NCI CTCAE wersja 4.0
Ramy czasowe: Do 3 miesięcy
Do 3 miesięcy
Czas do wystąpienia toksyczności związanej z leczeniem stopnia 3+, według oceny NCI CTCAE wersja 4.0
Ramy czasowe: Do 3 miesięcy
Do 3 miesięcy
Czas do nadirów hematologicznych (ANC, płytki krwi, hemoglobina) według oceny NCI CTCAE wersja 4.0
Ramy czasowe: Do 3 miesięcy
Do 3 miesięcy
Czas do progresji wg RECIST wersja 1.1
Ramy czasowe: Do 3 miesięcy
Do 3 miesięcy
Czas do niepowodzenia leczenia
Ramy czasowe: Od rejestracji do udokumentowania progresji, niedopuszczalnej toksyczności lub odmowy dalszego uczestnictwa przez pacjenta, oceniany do 3 miesięcy
Od rejestracji do udokumentowania progresji, niedopuszczalnej toksyczności lub odmowy dalszego uczestnictwa przez pacjenta, oceniany do 3 miesięcy
Adverse events profile, as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
Ramy czasowe: Up to 3 months

The number and severity of all adverse events (overall, by dose-level and diet, and by tumor group) will be tabulated and summarized.

Up to 3 months
Incidence of grade 3+ adverse events, as assessed by the NCI CTCAE version 4.0
Ramy czasowe: Up to 3 months

The number and severity of grade 3+ adverse events will be tabulated and summarized.

Up to 3 months
Toxicity profile, as assessed by the NCI CTCAE version 4.0
Ramy czasowe: Up to 3 months

Non-hematologic toxicities will be evaluated via the ordinal CTC standard toxicity grading. Hematologic toxicity measures of thrombocytopenia, neutropenia, and leukopenia will be assessed using continuous variables as the outcome measures (primarily nadir) as well as categorization via CTC standard toxicity grading. Overall toxicity incidence as well as toxicity profiles by dose level, patient and tumor site will be explored and summarized. Frequency distributions, graphical techniques and other descriptive measures will form the basis of these analyses.

Up to 3 months
Response profile, assessed using modified Response Evaluation Criteria in Solid Tumors (RECIST)
Ramy czasowe: Up to 3 months

Responses will be summarized by simple descriptive summary statistics delineating complete and partial responses as well as stable and progressive disease in this patient population The summary will be overall and by tumor group, and particularly by cohorts (first 34 patients vs. expansion cohort where a possibly refined definition of disease progression will be used).

Up to 3 months

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Pazopanib hydrochloride levels attained in response to standard dosing
Ramy czasowe: At baseline, at 24 hours after pazopanib hydrochloride and day 14 of course 1, and at 14 days of dosage change

Descriptive statistics, simple scatter plots and linear regression model will form the basis of presentation of these data. Attained levels will be correlated with cytochrome P450 and other polymorphisms and with observed toxicities.

At baseline, at 24 hours after pazopanib hydrochloride and day 14 of course 1, and at 14 days of dosage change
Steady state pazopanib hydrochloride trough levels
Ramy czasowe: 24 hours after initiation of 800 mg daily fasting

Descriptive statistics, simple scatter plots and linear regression model will form the basis of presentation of these data. Will be correlated with steady state trough levels after 14 days.

24 hours after initiation of 800 mg daily fasting
Trough pazopanib hydrochloride levels
Ramy czasowe: After 14 days of pazopanib hydrochloride administration

Descriptive statistics, simple scatter plots and linear regression model will form the basis of presentation of these data. Trough levels will be correlated with observed toxicities.

After 14 days of pazopanib hydrochloride administration

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Keith C Bible, Mayo Clinic

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

19 marca 2012

Zakończenie podstawowe (Rzeczywisty)

31 grudnia 2015

Ukończenie studiów (Szacowany)

31 marca 2027

Daty rejestracji na studia

Pierwszy przesłany

9 marca 2012

Pierwszy przesłany, który spełnia kryteria kontroli jakości

9 marca 2012

Pierwszy wysłany (Szacowany)

13 marca 2012

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

12 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

10 listopada 2026

Ostatnia weryfikacja

1 września 2026

Więcej informacji

Terminy związane z tym badaniem

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • NCI-2012-00690
  • P30CA015083 (Grant/umowa NIH USA)
  • U01CA069912 (Grant/umowa NIH USA)
  • UM1CA186686 (Grant/umowa NIH USA)
  • NCI-2012-00690 (Identyfikator rejestru: CTRP (Clinical Trial Reporting Program))
  • MAYO-MC1112
  • CDR0000727235
  • MC1112 (Inny identyfikator: Mayo Clinic in Rochester)
  • 9076 (Inny identyfikator: CTEP)
  • MC1112

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj